Bupivacaine-d9

Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine (Cay-16618) by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic. It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM. Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively). It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Cay-10009019). Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.Formal Name: 1-(butyl-d9)-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide. CAS Number: 474668-57-0. Molecular Formula: C18H19D9N2O. Formula Weight: 297.5. Purity: >99% deuterated forms (d1-d9). Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 25 mg/ml, Ethanol: 30 mg/ml. SMILES: CC1=CC=CC(C)=C1NC(C2N(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCCC2)=O. InChi Code: InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/i1D3,4D2,5D2,12D2. InChi Key: LEBVLXFERQHONN-JOJYFGIVSA-N.